Loading…
Reported covered position: Rep. Ed Whitfield: Legislative Correspondent, Legislative Assistant, Legislative Director, Chief of Staff; House Energy & Commerce Committee: Policy Coordinator, Subcommittee on Oversight & Investigations
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Issues related to drug pricing, including federal proposals impacting reimbursement, access, and affordability; Issues related to Medicare Drug negotiation and implementation of the Inflation Reduction Act; ORPHAN Cures Act and pharmacy benefit manager reform legislation (H.R. 1, One Big Beautiful Bill Act); Issues related to Most Favored Nation (MFN) pricing models
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2026 · third_quarter · Q3
Issues related to drug pricing, including federal proposals impacting reimbursement, access, and affordability; Issues related to Medicare Drug negotiation and implementation of the Inflation Reduction Act; Pharmacy benefit manager reform legislation; Issues related to Executive Order 14297- Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; Issues related to Most Favored Nation (MFN) pricing models
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Source: Senate LDA
Issues related to drug pricing; Issues related to the drug approval and review process; issues related to operations of the Department of Veterans Affairs including work with clinical trials and research studies; implementation of the Inflation Reduction Act; ORPHAN Cures Act and pharmacy benefit manager legislation; ORPHAN Cures Act language in H.R. 1, One Big Beautiful Bill Act
ORPHAN Cures Act
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Issues related to drug pricing, implementation of the Inflation Reduction Act, and the ORPHAN Cures Act (H.R. 5539); pharmacy benefit managers legislation; 340B drug discount program; the Food & Drug Administration; issues related to FDA Regulatory Framework and Interaction; informational inquiry related to the BIOSECURE Act (H.R. 7085)
ORPHAN Cures Act
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Issues related to drug pricing, implementation of the Inflation Reduction Act, and the ORPHAN Cures Act (H.R. 5539); pharmacy benefit managers legislation; the Food & Drug Administration; issues related to FDA Regulatory Framework and Interaction; informational inquiry related to the BIOSECURE Act (H.R. 8333)
BIOSECURE Act
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Issues related to drug pricing, implementation of the Inflation Reduction Act, and the ORPHAN Cures Act (H.R. 5539); pharmacy benefit managers legislation; 340B drug discount program; the Food & Drug Administration; issues related to FDA Regulatory Framework and Interaction; informational inquiry related to the BIOSECURE Act (H.R. 7085)
BIOSECURE Act
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Issues related to drug pricing, implementation of the Inflation Reduction Act, and the ORPHAN Cures Act (H.R. 5539); pharmacy benefit managers legislation; the Food & Drug Administration; issues related to FDA Regulatory Framework and Interaction; informational inquiry related to the BIOSECURE Act (H.R. 8333)
ORPHAN Cures Act
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Issues related to drug pricing, implementation of the Inflation Reduction Act, and the ORPHAN Cures Act (H.R. 5539); pharmacy benefit managers legislation; 340B drug discount program; the Food & Drug Administration; issues related to FDA Regulatory Framework and Interaction
Elijah E. Cummings Lower Drug Costs Now Act
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation; DIVERSE Trials Act
Elijah E. Cummings Lower Drug Costs Now Act
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation; DIVERSE Trials Act
Elijah E. Cummings Lower Drug Costs Now Act
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation; DIVERSE Trials Act
Elijah E. Cummings Lower Drug Costs Now Act
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation
Elijah E. Cummings Lower Drug Costs Now Act
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation
Elijah E. Cummings Lower Drug Costs Now Act
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation
William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Holding Foreign Companies Accountable Act (S. 945/H.R. 7000); H.Amdt. 847 to H.R. 6395 (FY 2021 National Defense Authorization Act)
Holding Foreign Companies Accountable Act
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Holding Foreign Companies Accountable Act (S. 945/H.R. 7000)
Holding Foreign Companies Accountable Act
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Holding Foreign Companies Accountable Act (S. 945/H.R. 7000); H.Amdt. 847 to H.R. 6395 (FY 2021 National Defense Authorization Act)
Holding Foreign Companies Accountable Act
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Holding Foreign Companies Accountable Act (S. 945/H.R. 7000); H.Amdt. 847 to H.R. 6395 (FY 2021 National Defense Authorization Act)
Holding Foreign Companies Accountable Act
Client: BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
Holding Foreign Companies Accountable Act (S. 945/H.R. 7000)
2026 · second_quarter · Q2
Issues related to drug pricing, including federal proposals impacting reimbursement, access, and affordability; Issues related to Medicare Drug negotiation and implementation of the Inflation Reduction Act; Pharmacy benefit manager reform legislation; Issues related to Executive Order 14297- Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; Issues related to Most Favored Nation (MFN) pricing models
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2026 · first_quarter · Q1
Issues related to drug pricing, including federal proposals impacting reimbursement, access, and affordability; Issues related to Medicare Drug negotiation and implementation of the Inflation Reduction Act; Pharmacy benefit manager reform legislation; Issues related to Most Favored Nation (MFN) pricing models
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2025 · fourth_quarter · Q4
Issues related to drug pricing, including federal proposals impacting reimbursement, access, and affordability; Issues related to Medicare Drug negotiation and implementation of the Inflation Reduction Act; Pharmacy benefit manager reform legislation; Issues related to Most Favored Nation (MFN) pricing models
Engaged with the Securities and Exchange Commission on a regulatory matter
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Securities & Exchange Commission (SEC)
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2025 · third_quarter · Q3
Issues related to drug pricing, including federal proposals impacting reimbursement, access, and affordability; Issues related to Medicare Drug negotiation and implementation of the Inflation Reduction Act; ORPHAN Cures Act and pharmacy benefit manager reform legislation (H.R. 1, One Big Beautiful Bill Act); Issues related to Most Favored Nation (MFN) pricing models
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2025 · second_quarter · Q2
Issues related to drug pricing; Issues related to the drug approval and review process; issues related to operations of the Department of Veterans Affairs including work with clinical trials and research studies; implementation of the Inflation Reduction Act; ORPHAN Cures Act and pharmacy benefit manager legislation; ORPHAN Cures Act language in H.R. 1, One Big Beautiful Bill Act
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2025 · first_quarter · Q1
Issues related to drug pricing; Issues related to the drug approval and review process; issues related to operations of the Department of Veterans Affairs including work with clinical trials and research studies; implementation of the Inflation Reduction Act; the EPIC Act; ORPHAN Cures Act and pharmacy benefit manager legislation.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2024 · fourth_quarter · 4A
Issues related to drug pricing, implementation of the Inflation Reduction Act, pharmacy benefit managers legislation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2024 · fourth_quarter · Q4
Issues related to drug pricing, implementation of the Inflation Reduction Act, pharmacy benefit managers legislation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2024 · third_quarter · Q3
Issues related to drug pricing, implementation of the Inflation Reduction Act, pharmacy benefit managers legislation; the Food & Drug Administration; and issues related to FDA Regulatory Framework and Interaction.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2024 · second_quarter · Q2
Issues related to drug pricing, implementation of the Inflation Reduction Act, and the ORPHAN Cures Act (H.R. 5539); pharmacy benefit managers legislation; the Food & Drug Administration; issues related to FDA Regulatory Framework and Interaction; informational inquiry related to the BIOSECURE Act (H.R. 8333)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2024 · first_quarter · Q1
Issues related to drug pricing, implementation of the Inflation Reduction Act, and the ORPHAN Cures Act (H.R. 5539); pharmacy benefit managers legislation; 340B drug discount program; the Food & Drug Administration; issues related to FDA Regulatory Framework and Interaction; informational inquiry related to the BIOSECURE Act (H.R. 7085)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2023 · fourth_quarter · Q4
Issues related to drug pricing, implementation of the Inflation Reduction Act, and the ORPHAN Cures Act (H.R. 5539); pharmacy benefit managers legislation; 340B drug discount program; the Food & Drug Administration; issues related to FDA Regulatory Framework and Interaction
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2023 · third_quarter · Q3
Issues related to implementation of the Inflation Reduction Act; pharmacy benefit managers legislation; 340B drug discount program; the Food & Drug Administration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2023 · second_quarter · Q2
Issues related to implementation of the Inflation Reduction Act; pharmacy benefit managers legislation; 340B drug discount program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2023 · first_quarter · Q1
Issues related to implementation of the Inflation Reduction Act, pharmacy benefit managers, and the 340B drug discount program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2022 · third_quarter · Q3
Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation; DIVERSE Trials Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2022 · second_quarter · Q2
Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation; DIVERSE Trials Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2022 · first_quarter · Q1
Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation; DIVERSE Trials Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2021 · fourth_quarter · Q4
Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2021 · third_quarter · Q3
Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2021 · second_quarter · Q2
Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2021 · first_quarter · Q1
Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2020 · fourth_quarter · Q4
Support first U.S. product launch and efforts to enhance company profile/reputation.
Holding Foreign Companies Accountable Act (S. 945/H.R. 7000)
Filing targets: HOUSE OF REPRESENTATIVES
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2020 · third_quarter · Q3
Holding Foreign Companies Accountable Act (S. 945/H.R. 7000); H.Amdt. 847 to H.R. 6395 (FY 2021 National Defense Authorization Act)
Support first U.S. product launch and efforts to enhance company profile/reputation.
Filing targets: HOUSE OF REPRESENTATIVES
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.) via BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)
2020 · third_quarter · RR
Support first U.S. product launch and efforts to enhance company profile/reputation; issues related to general business operations.
Support first U.S. product launch and efforts to enhance company profile/reputation; issues related to general business operations.
Support first U.S. product launch and efforts to enhance company profile/reputation; issues related to general business operations.
Support first U.S. product launch and efforts to enhance company profile/reputation; issues related to general business operations.
Support first U.S. product launch and efforts to enhance company profile/reputation; issues related to general business operations.
Support first U.S. product launch and efforts to enhance company profile/reputation; issues related to general business operations.